– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –

– Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients –

– Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

– New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings –

– First planned platform combination, darlifarnib + daraxonrasib in KRAS-mutant pancreatic cancer, expected to enter Phase 1a evaluation in early 2027 –

– Kura to host virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET to discuss darlifarnib data, platform strategy, and development plans –

SAN DIEGO, June 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today highlighted new clinical and translational data supporting darlifarnib as a potential foundational combination platform for KRAS-mutant cancers and other targeted therapy settings. The data, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, support Kura's strategy to expand its next-generation farnesyl transferase inhibitor (FTI) through a new platform study designed to efficiently evaluate multiple combinations and identify opportunities to improve the depth and durability of responses to targeted therapies.